Neurovascular protection by erythropoietin: from the bedside back to the bench.
Tufekci
Kemal Ugur
KU
Genc
Kursad
K
D004921:Erythropoietin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D019095:Point-of-Care Systems / Q000639:trends*; D017467:Receptors, Erythropoietin / Q000378:metabolism; D020521:Stroke / Q000378:metabolism / Q000517:prevention & control*; D015912:Thrombolytic Therapy / Q000009:adverse effects
D018696:Neuroprotective Agents; D017467:Receptors, Erythropoietin; D004921:Erythropoietin